—

Scholar Rock Holding Corp (SRRK) — Technical state

As of 2026-11-10 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 27 out of 100 (momentum 58 · quality 1), as of 2026-11-11.
  • Signal: Recovery attempt under the 200-day — Trades +2.5% vs the 50-day and -0.5% vs the 200-day average, 22.3% below the 52-week high and +66.7% off the 52-week low; a death cross printed 6 sessions ago. Computed from daily closes. (as of 2026-11-10)
  • Trend: Scholar Rock Holding Corp trades 2.5% above its 50-day and 0.5% below its 200-day moving average. (as of 2026-11-10)

Scholar Rock develops antibody drugs that target the latent, or inactive, forms of growth factors in the TGF-beta family, aiming to treat rare neuromuscular diseases. Its lead candidate, apitegromab, blocks myostatin activation and is in mid-stage trials for spinal muscular atrophy and facioscapulohumeral muscular dystrophy.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the SRRK overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Recovery attempt under the 200-day

Trades +2.5% vs the 50-day and -0.5% vs the 200-day average, 22.3% below the 52-week high and +66.7% off the 52-week low; a death cross printed 6 sessions ago. Computed from daily closes.

The moving-average stack

FAQ · from the current data · as of 2026-11-10

Quick answers

What is the current Closelooknet signal on SRRK?

Recovery attempt under the 200-day — Trades +2.5% vs the 50-day and -0.5% vs the 200-day average, 22.3% below the 52-week high and +66.7% off the 52-week low; a death cross printed 6 sessions ago. Computed from daily closes. As of 2026-11-10; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is SRRK above its 50-day and 200-day moving averages?

As of 2026-11-10, Scholar Rock Holding Corp trades +2.5% above its 50-day and -0.5% below its 200-day average, with the 20-day +10.5% away.

How far is SRRK from its 52-week high?

22.3% below the 52-week high and 66.7% above the 52-week low, as of 2026-11-10.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.